Compare AIR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIR | RCUS |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 1988 | 2018 |
| Metric | AIR | RCUS |
|---|---|---|
| Price | $82.42 | $21.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $89.00 | $29.38 |
| AVG Volume (30 Days) | 339.5K | ★ 2.1M |
| Earning Date | 01-06-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $2,858,400,000.00 | $240,000,000.00 |
| Revenue This Year | $12.82 | N/A |
| Revenue Next Year | $9.18 | N/A |
| P/E Ratio | $103.44 | ★ N/A |
| Revenue Growth | ★ 17.59 | N/A |
| 52 Week Low | $46.51 | $6.50 |
| 52 Week High | $89.69 | $26.40 |
| Indicator | AIR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 42.60 |
| Support Level | $78.62 | $20.35 |
| Resistance Level | $85.35 | $26.10 |
| Average True Range (ATR) | 2.61 | 1.48 |
| MACD | 0.20 | -0.59 |
| Stochastic Oscillator | 56.46 | 18.43 |
AAR Corp is engaged in providing products and services to aviation, government and defense market. It operates in segments namely: The parts supply segment majorly consists of sales and leasing of USM and aftermarket distribution of new, OEM-supplied replacement parts; Repair & Engineering segment provides airframe maintenance, component repair, and landing gear overhaul services; Integrated Solutions segment consists of its fleet management and operations of customer-owned aircraft, customized performance-based supply chain logistics programs in support of the U.S. Department of Defense, flight hour component inventory; and The Expeditionary Services segment consists of products and services supporting the movement of equipment and personnel by the U.S. and foreign governments and NGOs.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.